Mechanisms and prevention of Alloimmunization in pregnancy

Obstetrical and Gynecological Survey

Volumn 68, Issue 7, 2013, Pages 526-532

  Kjeldsen Kragh, Jens ^a   Skogen, Bjørn ^b,c  

^a University and Regional Laboratories Region Skane ^*  (Sweden)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ALLOANTIGEN; HYPERIMMUNE ANTIHUMAN PLATELET ANTIGEN; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; RHESUS D ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLOIMMUNIZATION; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ERYTHROCYTE; FETOMATERNAL TRANSFUSION; HELPER CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INCIDENCE; INNATE IMMUNITY; MOUSE; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NONHUMAN; PREGNANT WOMAN; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SYNCYTIOTROPHOBLAST; THROMBOCYTE; TROPHOBLAST;

ANTIGENS, HUMAN PLATELET; ERYTHROBLASTOSIS, FETAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; PREGNANCY; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84879860884     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3182947ce4     Document Type: Review

References (53)

1. Klein HG, Anstee DJ. Haemolytic Disease of the Fetus and the Newborn. Mollison's Blood Transfusion in Clinical Medicine. Oxford, UK: Blackwell Science Ltd; 2005:496-545
2. Bowman JM. RhD hemolytic disease of the newborn. N Engl J Med 1998;339:1775-1777
3. Clarke CA, Finn R,McConnell RB, et al. The protection afforded by ABO incompatability against erythroblastosis due to rhesus anti-D. Int Arch Allergy [Meeting Abstract] 1958;13:380
4. Prevention of Rh-haemolytic disease: results of the clinical trial. A combined study from centres in England and Baltimore. Br Med J 1966;2:907-914
5. Prevention of primary Rh immunization: first report of the Western Canadian trial, 1966-1968. Can Med Assoc J 1969; 100:1021-1024
6. Pollack W, Gorman JG, Freda VJ, et al. Results of clinical trials of RhoGAM in women. Transfusion 1968;8:151-153
7. Moulinier J, ed. Iso-immunisation maternelle anti-plaquettaire et purpura né o-natal. Le système de groupe plaquettaire 'Duzo'. Copenhagen: 6th Congress of the European Society of Hematology; 1957
8. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998;92:2280-2287 (Pubitemid 28452968)
9. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007;110:833-839 (Pubitemid 47267418)
10. Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to antiYHPA-1a. Transfusion 2005;45:1945-1956 (Pubitemid 43971423)
11. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001;41:45-55 (Pubitemid 32201293)
12. Kamphuis MM, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010;117:1335-1343
13. Voulgari PV, Paschou S, Svarna E, et al. Images in rheumatology. Transfusion-related acute lung injury during intravenous immunoglobulin treatment. J Rheumatol 2010;37:190-191
14. Maheshwari A, Christensen RD, Calhoun DA. Immune-mediated neutropenia in the neonate. Acta Paediatr Suppl 2002;91: 98-103 (Pubitemid 35347068)
15. Ponte M, Cantoni C, Biassoni R, et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A 1999;96:5674-5679 (Pubitemid 29234677)
16. Tilburgs T, Schonkeren D, Eikmans M, et al. Human decidual tissue contains differentiated CD8+ effector-memory T cells with unique properties. J Immunol 2010;185:4470-4477
17. Sacks G, Sargent I, Redman C. An innate view of human pregnancy. Immunol Today 1999;20:114-118
18. Messerli M, May K, Hansson SR, et al. Feto-maternal interactions in pregnancies: placental microparticles activate peripheral blood monocytes. Placenta 2010;31:106-112
19. Reil A, Keller-Stanislawski B, Gunay S, et al. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008;95:313-317
20. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997;99: 2139-2151 (Pubitemid 27203770)
21. Huppertz B, Kingdom J, Caniggia I, et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003;24: 181-190 (Pubitemid 37184714)
22. Johansen M, Redman CW, Wilkins T, et al. Trophoblast deportation in human pregnancyYits relevance for pre-eclampsia. Placenta 1999;20:531-539 (Pubitemid 29391296)
23. Kumpel BM, Sibley K, Jackson DJ, et al. Ultrastructural localization of glycoprotein IIIa (GPIIIa, beta 3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy. Transfusion 2008;48: 2077-2086
24. Eastlake J, Kumpel B. Effects of placental microparticles and platelets on in vitro cytokine profiles and their ability to cause an antiYHPA-1a antibody response in vivo. J Transfus Med 2012;2:65
25. Heddle NM, Soutar RL, O'Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 1995;91: 1000-1005
26. Hoeltge GA, Domen RE, Rybicki LA, et al. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. Arch Pathol Lab Med 1995;119:42-45
27. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-258 (Pubitemid 26130184)
28. Nace G, Evankovich J, Eid R, et al. Dendritic cells and damageassociated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun 2012; 4:6-15
29. Sirisinha S. Insight into the mechanisms regulating immune homeostasis in health and disease. Asian Pac J Allergy Immunol 2011;29:1-14
30. Chan PL, Sinclair NR. Regulation of the immune response. VI. Inability of F(ab) 2 antibody to terminate established immune responses and its ability to interfere with IgG antibodymediated immunosuppression. Immunology 1973;24:289-301
31. Sinclair NR, Lees RK, Elliott EV. Role of the Fc fragment in the regulation of the primary immune response. Nature 1968; 220:1048-1049
32. Crow AR, Freedman J, Hannach B, et al. Monoclonal antibodymediated inhibition of the human HLA alloimmune response to platelet transfusion is antigen specific and independent of Fcgamma receptorYmediated immune suppression. Br J Haematol 2000;110:481-487 (Pubitemid 30646881)
33. Karlsson MC, Wernersson S, Diaz de Stahl T, et al. Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptorYdeficient mice. Proc Natl Acad Sci U S A 1999;96:2244-2249 (Pubitemid 29117899)
34. Heyman B, Wiersma E, Nose M. Complement activation is not required for IgG-mediated suppression of the antibody response. Eur J Immunol 1988;18:1739-1743 (Pubitemid 19011581)
35. Heyman B, Wigzell H. Immunoregulation by monoclonal sheep erythrocyte-specific IgG antibodies: suppression is correlated to level of antigen binding and not to isotype. J Immunol 1984;132:1136-1143 (Pubitemid 14155348)
36. Stucki M, Schnorf J, Hustinx H, et al. Anti-D immunoglobulin in Rh(D) negative volunteers: clearance of Rh(D) positive red cells and kinetics of serum anti-D levels. Transfus Clin Biol 1998; 5:180-188 (Pubitemid 29151769)
37. Finn R, Clarke CA, Donohoe WT, et al. Experimental studies on the prevention of Rh haemolytic disease. Br Med J 1961; 1:1486-1490
38. Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007; 93:99-111 (Pubitemid 47228499)
39. Kumpel BM, Elson CJ. Mechanism of anti-DYmediated immune suppression Y a paradox awaiting resolution? Trends Immunol 2001;22:26-31 (Pubitemid 32675277)
40. Karlsson MC, Getahun A, Heyman B. FcgammaRIIB in IgGmediated suppression of antibody responses: different impact in vivo and in vitro. J Immunol 2001;167:5558-5564 (Pubitemid 33062744)
41. Brinc D, Le-Tien H, Crow AR, et al. Transfusion of IgGopsonized foreign red blood cells mediates reduction of antigen-specific B cell priming in a murine model. J Immunol 2008;181:948-953
42. Woodrow JC, Clarke CA, Donohow WT, et al. Mechanism of Rh prophylaxis: an experimental study on specificity of immunosuppression. Br Med J 1975;2:57-59
43. Chilcott J, Lloyd Jones M, Wight J, et al. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technol Assess 2003;7
44. MacKenzie IZ, Bowell P, Gregory H, et al. Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. Br J Obstet Gynaecol 1999;106: 492-497 (Pubitemid 29201531)
45. Mayne S, Parker JH, Harden TA, et al. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme. BMJ 1997;315:1588 (Pubitemid 27522400)
46. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-487 (Pubitemid 27343304)
47. Lo YM, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998;339:1734-1738 (Pubitemid 28555431)
48. Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D-pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012;52:752-758
49. Cooper N. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am 2009;23:1317-1327
50. Killie MK, Husebekk A, Kjeldsen-Kragh J, et al. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008;93:870-877. (Pubitemid 351821723)
51. Skogen B, Killie MK, Kjeldsen-Kragh J, et al. Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention. Expert Rev Hematol. 2010;3: 559-566.
52. Tiller H, Killie MK, Chen P, et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion. 2012;52:1446-1457.
53. Kjeldsen-Kragh J, Ni H, Skogen B. Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia. Curr Opin Hematol. 2012;19:469-474.